Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

Clinical trial NCT00268710 · COMPLETED

Trial details

NCT number: NCT00268710
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Prostatic Neoplasms

Start date: 2004-02-01
Primary completion: 2006-03-01

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.